Ads
related to: merck & co.
Search results
Why Merck (MRK) is a Top Momentum Stock for the Long-Term
Zacks· 6 days agoFor new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Benzinga via Yahoo Finance· 3 days agoKeytruda (pembrolizumab) is Merck & Co Inc’s (NYSE:MRK) top selling cancer drug. The abstract...
Tango terminates USP1 inhibitor programme
Clinical Trials Arena via Yahoo Finance· 4 days agoThe company’s market cap stands at $757.5m. Tango also planned to evaluate its therapy in combination with AstraZeneca’s and Merck & Co’s poly-ADP ribose...
Lilly partners with Aktis, deepening radiopharma investment
BioPharma Dive via Yahoo Finance· 7 days agoBristol Myers Squibb and Novartis, the latter of which has two approved radiopharmaceuticals,...
What's the Goal in Treating Type 2 Diabetes?
Medscape· 5 days agoAnne Peters discusses the differences in the newly published American College of Physicians and the American Diabetes Association guidelines for treating...
Why Merck (MRK) is a Top Momentum Stock for the Long-Term
Zacks via Yahoo Finance· 6 days agoMerck (MRK) Based in Kenilworth, NJ, Merck & Co. boasts more than six blockbuster products in its...
Edward Scolnick
GBH News· 2 days agoEdward Scolnick is director of the Psychiatric Disease Program and the Stanley Center for Psychiatric Research at the Broad Institute and a senior...
Madison-based life science company Mirus Bio to be acquired for $600 million
Small Business Times· 4 days agoMadison-based Mirus Bio, a manufacturer of transfection regents used in gene therapies, has entered...
Weight-Loss Upstart Viking Needs a Deal to Vie With Lilly and Novo
Bloomberg via Yahoo Finance· 6 days ago(Bloomberg) -- Hope for a weight-loss drug that’s better than Ozempic and Wegovy has sent Viking...
AstraZeneca’s $80B sales plan leans on cancer drug expansion
BioPharma Dive via Yahoo Finance· 6 days agoImfinzi, the company’s flagship immunotherapy, arrived fifth to market in the U.S. and last year...
